Helius Medical Technologies, Inc. Reports Third Quarter 2022 Financial Results
Helius Medical Technologies (HSDT) reported a strong Q3 2022 with total revenue soaring by 80% to $196,000 compared to $109,000 in Q3 2021. This is attributed to the commercial availability of PoNS Therapy, which has gained positive market traction. The company raised $18 million in a public offering, providing $16.7 million in cash reserves for operations through 2023. Operating loss increased to $4.9 million, but net loss improved to $1 million from $4.7 million year-over-year, indicating a shift towards operational stability.
- Q3 2022 revenue increased by 80% to $196,000, up from $109,000 in Q3 2021.
- Secured $18 million in a public offering, raising approximately $16.3 million in net proceeds.
- Cash on hand of $16.7 million expected to fund operations through 2023.
- Successful rollout of PoNS Therapy with training for nearly 100 physical therapists.
- Operating expenses rose to $4.9 million, up from $4.4 million in Q3 2021.
- Operating loss increased by $0.5 million to $4.9 million compared to the previous year.
-- Total Q3 revenue up
-- Cash on hand expected to fund operations through 2023 --
-- Company to host call at 8:30am today --
NEWTOWN, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported financial results for the quarter ended September 30, 2022.
Third Quarter and Recent Business Updates
- First full quarter of commercial availability of PoNS® in the U.S.
- Introduced online, on-demand training module to standardize and streamline the training of physical therapists who wish to use PoNS Therapy to treat patients suffering gait impairment due to multiple sclerosis (MS).
- Added MGH Institute of Health Professions (“Mass General”) and Oregon Health & Science University (“OHSU”) as Therapeutic Experience Program (TEP) centers of excellence joining Shepard Center in Atlanta and NYU Langone, who are already enrolling patients.
- Closed an
$18 million public offering, raising net proceeds of approximately$16.3 million . - Q3 2022 revenue increased by
80% to$196 thousand compared to$109 thousand in Q3 2021, and by65% compared to Q2 2022. $16.7 million of cash on hand to fund operations through 2023.
“It was the first full quarter of commercial sales and the market response to PoNS Therapy remains strong, as demonstrated by the quarter over quarter increase in US sales. The Patient Therapy Access Program we introduced in June has been well received, and a significant percentage of patients have used PTAP to access on-label PoNS Therapy at a reduced price. We also addressed another major impediment to access with our online training module which has allowed us to greatly accelerate the training of physical therapists. In the US, we have gone from less than half a dozen to close to 100 PTs trained over the past three months, with the large majority occurring since we kicked off the program. Because physical therapists can now receive PoNS Therapy training on-demand in three hours or less, instead of through an in-person, multi-day course, patients can have readily available access to PoNS trained therapists,” said Dane Andreeff, President and Chief Executive Officer of Helius.
“We also made progress with TEP, an important program that will help us gather information about the effectiveness of PoNS Therapy in a real-world environment. During the quarter, we began enrollment at the previously announced TEP locations and, more recently, added Mass General and OHSU as Centers of Excellence. We are energized by all the Company has accomplished in 2022 so far and, fortified by our recent equity raise, look forward to continuing the momentum into next year and beyond, bringing relief to as many patients as possible who suffer from gait impairment,” concluded Mr. Andreeff.
Third Quarter 2022 Financial Results
Total revenue for the third quarter of 2022 was
For the three months ended September 30, 2022, cost of sales was
Operating expenses for the third quarter of 2022 increased to
Operating loss for the third quarter of 2022 increased
Net loss was
As of September 30, 2022, the Company had cash of
Fourth Quarter and Near-Term Guidance
The Company currently expects fourth quarter revenue to be modestly above the third quarter levels, factoring in the timing required to pair patients with trained physical therapists. In addition, as we near the end of the fourth quarter, we may experience some patients delaying PoNS treatment until after the holidays, which could temper sales growth as we expand our U.S. market penetration. As we continue to build momentum and expand our sales coverage, the Company expects future quarterly revenue to continue increasing sequentially quarter over quarter throughout 2023 as the U.S. commercialization of PoNS develops.
Conference Call
As previously announced, management will host a conference call as follows:
| Date: | Monday, November 14, 2022 |
| Time: | 8:30 AM ET |
| Register* (Audio Only): | Click Here |
| Webcast: | https://edge.media-server.com/mmc/p/k92nxahw |
The webcast will be archived under the Newsroom section of the Company’s investor relations website.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brain’s ability to compensate and promote neuroplasticity, improving the lives of people dealing with neurologic diseases.
The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS®). For more information, visit www.heliusmedical.com.
About the PoNS Device and PoNS Therapy
The Portable Neuromodulation Stimulator (PoNS) is an innovative non-surgical medical device, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the surface of the tongue to improve balance and gait. The PoNS device is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. Helius is advancing PoNS post-approval research in MS through a recently launched Therapeutic Experience Program (TEP) designed to partner with neurologists and neurorehabilitation therapists at 10-12 US centers of excellence, who express an interest in becoming “early adopters” of PoNS therapy. For more information visit www.ponstherapy.com.
PoNS is also authorized for sale in Canada for two indications: (i) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy; and (ii) for use as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy. PoNS is also authorized for sale in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait.
Cautionary Disclaimer Statement:
Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as “believe,” “continue,” “expect,” “will,” “goal,” “aim to” and similar expressions. Such forward-looking statements include, among others, statements regarding the Company’s future growth and operational progress, including commercial activities for the PoNS device, projected revenue from sales of our products, progress of commercialization of the PoNS device in the U.S., the ability and timing of our customers’ ability to seek reimbursement for the PoNS device in the U.S., expectations for the Therapeutic Experience Program, clinical development plans, and product development activities.
There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include uncertainties associated with the Company’s capital requirements to achieve its business objectives, availability of funds, the ability to find additional sources of funding, the impact of the COVID-19 pandemic, manufacturing, labor shortage and supply chain risks, the Company’s ability to train physical therapists in the supervision of the use of the PoNS treatment, the Company’s ability to secure contracts with rehabilitation clinics, the Company’s ability to obtain national Medicare coverage and to obtain a reimbursement code so that the PoNS device is covered by Medicare and Medicaid, the Company’s ability to build internal commercial infrastructure, secure state distribution licenses, build a commercial team and build relationships with Key Opinion Leaders, neurology experts and neurorehabilitation centers, market awareness of the PoNS device, future clinical trials and the clinical development process, ongoing government regulation and other factors, and other risks detailed from time to time in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2022 and June 30, 2022 and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at www.sec.gov or www.sedar.com.
The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.
Investor Relations Contact:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Helius Medical Technologies, Inc.
Unaudited Condensed Consolidated Statements of Operations
(Amounts in thousands except shares and per share data)
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Revenue | ||||||||||||||||
| Product sales, net | $ | 195 | $ | 102 | $ | 497 | $ | 242 | ||||||||
| Other revenue | 1 | 7 | 8 | 22 | ||||||||||||
| Total revenue | 196 | 109 | 505 | 264 | ||||||||||||
| Cost of revenue | 101 | 86 | 313 | 169 | ||||||||||||
| Gross profit | 95 | 23 | 192 | 95 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Selling, general and administrative | 3,393 | 2,859 | 8,673 | 9,800 | ||||||||||||
| Research and development | 751 | 1,489 | 3,468 | 4,182 | ||||||||||||
| Amortization expense | 47 | 48 | 141 | 153 | ||||||||||||
| Goodwill impairment | 757 | — | 757 | — | ||||||||||||
| Total operating expenses | 4,948 | 4,396 | 13,039 | 14,135 | ||||||||||||
| Loss from operations | (4,853 | ) | (4,373 | ) | (12,847 | ) | (14,040 | ) | ||||||||
| Nonoperating income (expense) | ||||||||||||||||
| Interest expense, net | (919 | ) | — | (919 | ) | — | ||||||||||
| Change in fair value of derivative liability | 5,489 | — | 5,489 | — | ||||||||||||
| Foreign exchange (loss) gain | (747 | ) | (314 | ) | (910 | ) | 10 | |||||||||
| Other income, net | — | — | 1 | — | ||||||||||||
| Nonoperating income (expense), net | 3,823 | (314 | ) | 3,661 | 10 | |||||||||||
| Loss before provision for income taxes | (1,030 | ) | (4,687 | ) | (9,186 | ) | (14,030 | ) | ||||||||
| Provision for income taxes | — | — | — | — | ||||||||||||
| Net loss | $ | (1,030 | ) | $ | (4,687 | ) | $ | (9,186 | ) | $ | (14,030 | ) | ||||
| Net loss per share | ||||||||||||||||
| Basic | $ | (0.12 | ) | $ | (2.01 | ) | $ | (0.52 | ) | $ | (6.29 | ) | ||||
| Diluted | $ | (0.12 | ) | $ | (2.01 | ) | $ | (0.52 | ) | $ | (6.29 | ) | ||||
| Weighted average number of common shares outstanding | ||||||||||||||||
| Basic | 8,543,303 | 2,326,893 | 17,761,752 | 2,229,422 | ||||||||||||
| Diluted | 8,543,303 | 2,326,893 | 17,761,752 | 2,229,422 | ||||||||||||
Helius Medical Technologies, Inc.
Unaudited Condensed Consolidated Balance Sheets
(Except for share data, amounts in thousands)
| September 30, 2022 | December 31, 2021 | |||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash | $ | 16,658 | $ | 11,005 | ||||
| Accounts receivable, net | 21 | 66 | ||||||
| Other receivables | 196 | 185 | ||||||
| Inventory, net | 609 | 476 | ||||||
| Prepaid expenses and other current assets | 733 | 862 | ||||||
| Total current assets | 18,217 | 12,594 | ||||||
| Property and equipment, net | 348 | 409 | ||||||
| Goodwill | — | 763 | ||||||
| Intangible assets, net | 178 | 333 | ||||||
| Operating lease right-of-use asset, net | 116 | 3 | ||||||
| Total assets | $ | 18,859 | $ | 14,102 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 570 | $ | 1,069 | ||||
| Accrued liabilities | 551 | 1,433 | ||||||
| Operating lease liabilities | 53 | 3 | ||||||
| Deferred revenue | 26 | 148 | ||||||
| Total current liabilities | 1,200 | 2,653 | ||||||
| Operating lease liabilities | 70 | — | ||||||
| Deferred revenue | 173 | 193 | ||||||
| Derivative liability | 4,455 | — | ||||||
| Total liabilities | 5,898 | 2,846 | ||||||
| STOCKHOLDERS’ EQUITY | ||||||||
| Class A common stock, 3,780,674 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively | 28 | 4 | ||||||
| Additional paid-in capital | 159,386 | 149,412 | ||||||
| Accumulated deficit | (146,221 | ) | (137,035 | ) | ||||
| Accumulated other comprehensive loss | (232 | ) | (1,125 | ) | ||||
| Total stockholders' equity | 12,961 | 11,256 | ||||||
| Total liabilities and stockholders' equity | $ | 18,859 | $ | 14,102 | ||||
FAQ
What was Helius Medical Technologies' revenue for Q3 2022?
What factors contributed to the increase in revenue for HSDT?
How much cash does Helius Medical Technologies have on hand?
What are the future revenue expectations for HSDT?
